Takashi Kamigaki
Overview
Explore the profile of Takashi Kamigaki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
466
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kamigaki T, Takimoto R, Okada S, Ibe H, Oguma E, Goto S
Anticancer Res
. 2024 Aug;
44(9):3713-3724.
PMID: 39197920
Cancer immunotherapy activates the host immune system against tumor cells and has the potential to lead to the development of innovative strategies for cancer treatment. Neoantigens are non-self-antigens produced by...
2.
Okazawa Y, Kamigaki T, Sugimoto K, Yamada T, Yoshida Y, Okada S, et al.
Oncol Lett
. 2024 Feb;
27(3):101.
PMID: 38298433
The safety and efficacy of combination therapy of immune cell therapy and chemotherapy [chemo-adoptive immunotherapy (CAIT)] for patients with stage IV or recurrent colorectal cancer have been reported. In the...
3.
Kida A, Mizukoshi E, Kitahara M, Miyashita T, Goto S, Kamigaki T, et al.
Int J Cancer
. 2023 Sep;
154(4):738-747.
PMID: 37676069
The identification of immune cell profiles (ICP) involved in anti-tumor immunity is crucial for immunotherapy. Therefore, we herein investigated cholangiocarcinoma patients (CCA) who received adoptive T-cell immunotherapy (ATI). Eighteen unresectable...
4.
Takimoto R, Kamigaki T, Ito H, Saito M, Takizawa K, Soejima K, et al.
Cytotherapy
. 2023 Jul;
25(11):1229-1235.
PMID: 37486281
Background Aims: With the aim of strengthening the scientific evidence of immune-cell therapy for cancer and further examining its safety, in October 2015, our hospital jointly established the Cancer Immune-Cell...
5.
Takimoto R, Kamigaki T, Okada S, Ibe H, Oguma E, Goto S
Anticancer Res
. 2022 Jul;
42(8):4179-4187.
PMID: 35896218
Background/aim: The efficacy of adjuvant systemic therapy after surgical resection remains unsatisfactory; therefore, a new treatment strategy is required. We aimed to examine the efficacy of adjuvant immune-cell therapy using...
6.
Li S, Ma J, Hong X, Zheng M, Goto S, Takimoto R, et al.
Transl Cancer Res
. 2022 Feb;
8(2):693-698.
PMID: 35116802
Significant clinical response was obtained in a patient with stage IV colorectal cancer (CRC) following combination therapy involving capecitabine and adoptive cell transfer therapy. She had laparoscopic lower anterior resection...
7.
Takimoto R, Kamigaki T, Okada S, Ibe H, Oguma E, Goto S
Anticancer Res
. 2021 Jul;
41(8):4133-4141.
PMID: 34281884
Background/aim: Advanced/recurrent breast cancer (ARBC) still has a poor prognosis; therefore, new treatment strategies are required. In this retrospective study, we aimed to investigate the efficacy of immune-cell therapy using...
8.
Takimoto R, Kamigaki T, Gotoda T, Takahashi T, Okada S, Ibe H, et al.
J Med Case Rep
. 2021 Apr;
15(1):191.
PMID: 33827668
Background: Blocking the programmed death 1 pathway by immune checkpoint inhibitors induces dramatic antitumor activity in patients with malignant tumors. However, the clinical response to immune checkpoint inhibitors remains limited...
9.
Kumai T, Mizukoshi E, Hashiba T, Nakagawa H, Kitahara M, Miyashita T, et al.
Cytotherapy
. 2020 Sep;
23(2):137-145.
PMID: 32907781
Background Aims: Immunotherapy is effective for many types of cancer, but its benefits in advanced pancreatic cancer, which has a poor prognosis, are not well established. In this study, the...
10.
Yamada T, Yoshida Y, Maeda T, Yoshimatsu G, Aisu N, Yamashita K, et al.
Anticancer Res
. 2020 Jul;
40(8):4763-4771.
PMID: 32727803
Background/aim: Chemoimmunotherapy is a promising treatment for various malignant diseases. In this study, we examined whether first-line chemoimmunotherapy using adoptive immune-cell therapy was effective for metastatic colorectal cancer (mCRC). Patients...